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Metastasis is the most life threatening aspect of breast cancer. It is a multi-step process involving in-
vasion and migration of primary tumor cells with a subsequent colonization of these cells at a secondary
location. The aim of the present study was to investigate the role of thioredoxin (Trx1) in the invasion
and migration of breast cancer cells and to assess the strength of the association between high levels of
Trx1 and thioredoxin reductase (TrxR1) expression with breast cancer patient survival. Our results in-
dicate that the expression of both Trx1 and TrxR1 are statistically signiﬁcantly increased in breast cancer
patient cells compared with paired normal breast tissue from the same patient. Over-expression of Trx1
in MDA-MB-231 breast cancer cell lines enhanced cell invasion in in vitro assays while expression of a
redox inactive mutant form of Trx1 (designated 1SS) or the antisense mRNA inhibited cell invasion.
Addition of exogenous Trx1 also enhanced cell invasion, while addition of a speciﬁc monoclonal antibody
that inhibits Trx1 redox function decreased cell invasion. Over-expression of intracellular Trx1 did not
increase cell migration but expression of intracellular 1SS inhibited migration. Addition of exogenous
Trx1 enhanced cell migration while 1SS had no effect. Treatment with auranoﬁn inhibited TrxR activity,
cell migration and clonogenic activity of MDA-MB-231 cells, while increasing reactive oxygen species
(ROS) levels. Analysis of 25 independent cohorts with 5910 patients showed that Trx1 and TrxR1 were
both associated with a poor patient prognosis in terms of overall survival, distant metastasis free survival
and disease free survival. Therefore, targeting the Trx system with auranoﬁn or other speciﬁc inhibitors
may provide improved breast cancer patient outcomes through inhibition of cancer invasion and mi-
gration.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).B.V. This is an open access article u
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Oxidative stress is a characteristic feature of many cancers,
including breast cancer, and has been implicated in cancer de-
velopment and progression [1–4]. Higher levels of reactive oxygen
species (ROS) are generated through the increased metabolic ac-
tivity of cancer cells, enhanced signaling pathways or mitochon-
drial dysfunction [5]. As a consequence many antioxidants and
redox control systems are up-regulated, suggesting that a balance
of ROS levels is important to maintain cancer cell function [6]. One
of the most important cellular cytoplasmic redox systems is the
thioredoxin (Trx) system, comprised of Trx1, thioredoxin reductase
(TrxR1) and NADPH [7] and it is highly expressed in many cancer
cells, including breast tumors [8].
Thioredoxins are small (12 KDa) redox active proteins with a
highly conserved active dithiol containing site of –Cys–Gly–Pro–
Cys–, which participates in redox reactions through a reversible
oxidation cycle [7]. The reduced Trx protein is a very effective
protein disulﬁde reductase and through this action it is able tonder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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causing the activation or inhibition of target proteins. The oxidized
Trx is then reduced by the NADPH dependent TrxR [7].
Multiple protein substrates have been identiﬁed for Trx1, in-
cluding ribonucleotide reductase [7], various transcription factors
[9,10], peroxiredoxins [11] and the methionine sulfoxide re-
ductases [12]. Furthermore Trx1 can also act as a direct scavenger
of ROS [13] and reduced Trx1 inhibits apoptosis by binding to ASK-
1 [14]. Involvement of Trx1 in protecting cells from apoptosis has
many consequences for cancer, in terms of maintaining cell via-
bility and protection from various chemotherapeutic treatments
[15,16].
Over recent years the Trx1 system has been linked with tumor
development and cancer. Both Trx1 and TrxR1 are highly ex-
pressed in many cancer cell lines, [17–20] and in patient tumors
compared to corresponding normal tissue [8,21–23]. Signiﬁcant
evidence links the expression of the Trx1 system with the pro-
liferative capacity and the apoptotic resistance of different cancers.
An in vivo study observed a positive correlation between Trx1
over-expression and cancer cell proliferation and decreased
apoptosis in primary gastric carcinomas, which correlated with a
poor clinical outcome [21]. Other studies have shown similar
correlations with high Trx1 levels and decreased patient survival
levels in non-small cell lung carcinoma [22] and colorectal cancer
[23]. An association between high levels of Trx1 expression and
the aggressiveness of tumors in human lung cancer [24], prostate
carcinoma [25] and in skin cancers and mammary tumors [8] has
also been observed.
An increase in Trx1 levels does not occur just as a consequence
of cancer growth but rather, Trx1 has an active functional role in
cancer metastasis and progression [6]. Several studies have been
conducted using breast cancer cells to assess the role of Trx1 in
cancer development and invasive processes. An early study
showed that transfection of MCF-7 breast cancer cells with the
gene encoding a redox inactive mutated Trx1 protein (with both
active site cysteines mutated) reversed the transformed pheno-
type of cancer cells with the expressed protein acting in a domi-
nant negative manner. When the transfected MCF-7 cells were
inoculated into scid mice, tumor formation was almost completely
suppressed with only microscopic tumor cell deposits being ob-
served and no evidence of metastasis to other organs [26].
Trx1 expression has also been associated with the regulation of
other molecules that are necessary for breast cancer cell invasion,
including vascular endothelial growth factor (VEGF) and matrix
metalloproteinase-9 (MMP-9). Transfection of MCF-7 breast cancer
cells with a construct that over-expresses Trx1 increased VEGF
production and secretion in vitro while transfection of constructs
expressing the redox-inactive Trx1 protein resulted in a decrease
of VEGF expression [27]. Transfection of the MDA-MB-231 breast
cancer cell line with a Trx1 expressing construct resulted in an
increase of MMP-9 expression and also enhanced cell invasion of
these transfected cells in vitro, while transfection with a construct
expressing the redox inactive protein resulted in decreased MMP-
9 expression and decreased cancer cell invasion [28]. A previous
study had shown that Trx1 preferentially inhibits the tissue in-
hibitor of metalloproteinases (TIMPs) so that MMP activity is fa-
vored, leading to extracellular matrix degradation and an increase
in cancer cell invasion [29]. These results suggest that Trx1 plays
an active role in regulating processes that lead to increased cancer
cell invasion.
Trx1 also has extracellular functions. Trx1 can be secreted by
cells by a non-classical pathway [19] and can act as an autocrine
growth factor as well as displaying co-cytokine activity augment-
ing the effects of other cytokines [30]. Extracellular Trx1 may be
bound to the external cell membrane where it may participate in
and regulate cell to cell contact and contribute to redox regulationin the extracellular space [31]. Redox processes in the extracellular
environment that involve Trx1 have also been linked to regulation
of cellular processes that encompass cell differentiation, pro-
liferation and death [32,33]. This leads to the possibility that Trx1
may also control the progression or metastatic pathways of cancer
cells through an extracellular activity [34]. A recent study showed
that Trx1 is present at high levels in the serum of breast cancer
patients [35] and it is therefore feasible for Trx1 to have extra-
cellular roles in breast cancer.
This study deﬁnes the active site of Trx1 as required for sti-
mulating cancer cell invasion and migration. Inhibition of the Trx1
system through the addition of auranoﬁn, an inhibitor of TrxR1,
also decreased the cell migration capacity of the breast cancer
cells. We also show that tumor tissue isolated from breast cancer
patients has higher Trx1 and TrxR1 expression than from the
paired normal tissue. Patients with high Trx1 and TrxR1 expres-
sion levels were also shown to have poor outcomes in terms of
overall survival, distant-metastasis free survival, and disease free
survival.2. Materials and methods
2.1. Cells and reagents
The human breast cancer cell line, MDA-MB-231 was obtained
from Prof. Erik Thompson (Queensland University of Technology,
Brisbane Australia). Cells were cultured in RPMI-1640 medium
containing 10% (v/v) fetal bovine serum (FBS), 200 mM L-gluta-
mine, and 100 U/ml penicillin and 100 μg/ml streptomycin (In-
vitrogen, VIC, Australia). Auranoﬁn was purchased from ICN Bio-
medicals (NSW, Australia). The anti-human Trx1 monoclonal an-
tibodies, 9G9 and 2B1, were made and characterized for their Trx1
binding properties as described previously [32]. Recombinant
human Trx1 and the redox inactive mutated form of human Trx1
(designated 1SS) was expressed and puriﬁed as previously de-
scribed [36]. All chemicals were purchased from Sigma (NSW,
Australia) unless otherwise stated.
2.2. Gene expression data and survival analysis
We used 25 gene expression datasets obtained by microarray
analysis of tumor specimens from a total of 4839 patients with
primary breast cancers (Table 1). The Cancer Genome Atlas (TCGA)
Data Portal was queried for RNA-seq expression and clinical in-
formation (n¼1071) of breast invasive carcinoma patients (last
update May 2015). Details on data generation are available in the
original TCGA study [37]. The normalized gene expression results
analyzed according to the RNASeqV2 protocol were obtained from
the TCGA portal. Analysis was restricted to patients with matched
tumor and normal samples (n¼114). The statistical signiﬁcance (p-
value) of the difference in expression levels for a gene was cal-
culated using a two-sample paired t test.
For survival analysis patients were dichotomized based on gene
expression levels. The optimal cut-points were searched within
the inner 80% selection interval and chosen based on a minimal
corrected p-value as proposed by Altman and colleagues [38] and
based on maximum Harrell's C indices [39]. Kaplan Meier esti-
mator of survival was used to visualize the survival curves. Hazard
ratio and the logrank test were used to compare overall survival
(OS), distant metastasis-free survival (DMFS) and disease free
survival (DFS) between patients in different groups. All analyses
were performed using the statistical software environment R
(package survival).
Table 1
Datasets used for gene expression analysis. Total n¼ 5910
Dataset Microarray technology Survival
data
No. of
patients
PMID
TCGA RNA-seq OS 1071 23000897
E-TABM-158 Affymetrix HGU OS, DMFS,
DFS
117 17157792
GSE11121 Affymetrix HGU DMFS 200 18593943
GSE12093 Affymetrix HGU DMFS 136 18821012
GSE12276 Affymetrix HGU DMFS 204 19421193
GSE17705 Affymetrix HGU DMFS 298 20697068
GSE19615 Affymetrix HGU DMFS 155 20098429
GSE25066 Affymetrix HGU OS 508 21558518
GSE2603 Affymetrix HGU DMFS 82 16049480
GSE2990 Affymetrix HGU DMFS, DFS 187 16478745
GSE3143 Affymetrix HGU OS 171 16273092
GSE5327 Affymetrix HGU DMFS 58 17420468
GSE6532 Affymetrix HGU DMFS 114 17401012
GSE7390 Affymetrix HGU OS, DMFS,
DFS
198 17545524
GSE9195 Affymetrix HGU DMFS, DFS 77 18498629
GSE18229 Agilent OS, DFS 252 20813035
Van de Vijver Agilent OS, DFS 296 12490681
E-UCON-1 Agilent DFS 305 22366898
GSE1379 Arcturus 22k human
oligonucleotide
microarray
DFS 60 15193263
GSE1456 Affymetrix HGU DFS 159 16280042
GSE2034 Affymetrix HGU DFS 286 15721472
GSE3494 Affymetrix HGU DFS 236 16141321
GSE4922 Affymetrix HGU DFS 249 17079448
GSE6532 Affymetrix HGU DFS 241 17401012
Vant'Veer Agilent DFS 95 11823860
GSE9893 MLRG Human 21K V12.0 OS 155 18347175
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The constructs used for the cell invasion studies that expressed
either wild-type Trx1 (pTrx-wt) or the 1SS redox inactive mutated
form of Trx1 (pTrx-1SS) from the pcDNA3.1 vector were described
previously [40]. To generate the antisense construct the wild-type
Trx1 coding sequences were inserted into the pcDNA3.1 vector in
the opposite direction with respect to the CMV promoter (pTrx-
as). The constructs used for the cell migration work were made by
excising the wild type Trx1 coding sequences or the 1SS redox
inactive mutant sequences from the pTrx-wt and pTrx-1SS con-
structs and inserting into pIRES-EGFP (Clontech, CA, USA) to
generate pGFP-Trx and pGFP-1SS.2.4. Production and analysis of stable cell lines
For the cancer cell invasion studies MDA-MB-231 breast cancer
cells were transfected with pTrx-wt, pTrx-1SS, pTrx-as and
pcDNA3.1 using Lipofectamine 2000 (Invitrogen), according to the
manufacturer’s instructions. Cells were grown for 3 weeks in
1000 μg/ml geneticin (Sigma). At least three clones from each
transfection were randomly selected for further investigation and
the data presented for the invasion and migration studies using
the stable cell lines is combined from individual analysis of each
clone. Conﬁrmation of the construct was obtained by PCR of
genomic DNA of each clone and subsequent sequencing of the
ampliﬁed product. Speciﬁc expression from each construct in each
clone was conﬁrmed by quantitative RT-PCR using primers speciﬁc
for the construct. For cell migration studies MDA-MB-231 breast
cancer cells were transfected with pIRES-GFP, pGFP-Trx and pGFP-
1SS as described above except that ﬂuorescence was also used to
conﬁrm expression of the constructs.2.5. Cell invasion assay
Assays were performed based on the Boyden chamber invasion
method described previously [41]. Essentially, a 13 mm diameter
polycarbonate ﬁlter with 12 μm pores (Neuro Probe, MD, USA) was
coated with a 1:30 dilution of Matrigel (BD Biosciences, NSW,
Australia) (17 μg/50 μL) and placed over the lower well of the
Boyden chamber that had been ﬁlled with RPMI containing 10%
FBS. The upper compartment was then created by screwing in the
retainer with a rubber washer placed above the Matrigel-coated
membrane. Then 2.5105 MDA-MB-231 cells were added to the
upper compartment. Cells were allowed to invade for 9 h, and then
the cells on the lower surface of the ﬁlter were stained using the
Quick-Dip dye system (Histolabs, NSW, Australia). The ﬁlter was
mounted for microscopy, and the cells present in ﬁve low-power
ﬁelds (100 total magniﬁcation) on each ﬁlter were counted. The
experiments were done in triplicate and repeated 3 times. When
adding reduced recombinant human Trx1, samples were treated
with 0.5 mM DTT for 15 min at 37 °C prior to addition to the
bottom well of the chamber.
2.6. Cell proliferation assays
The MDA-MB-231 cells were seeded in triplicate in sterile 96-
well plates at a density of 3104 cells/well and cultured in a CO2
incubator for 24 h before the medium was removed and replaced
with 0.1% serum containing media. Plates were then incubated for
a further 24 h, after which the media was removed and replaced
with 200 ml of media containing auranoﬁn. Cell growth was
measured 24 h after auranoﬁn addition. 5 mg/ml MTT (ICN Bio-
chemicals), prepared using sterile ﬁltered 1 PBS, was added to
each well and incubated for 3 h. 50 ml of 20% (w/v) SDS in 0.01 M
HCl was then added to each well. The plates were incubated
overnight and then read on a Spectramax M3 Plate Reader (Mo-
lecular Devices, Vic, Australia) at a wavelength of 570 nm. All as-
says were measured in triplicate from experiments performed
3 times.
2.7. TrxR activity assays
The activity assays were based on previously described proce-
dures [42]. Cells were lysed in 200 ml NP-40 extraction buffer
(150 mM NaCl; 50 mM Tris-Cl, pH 8; 0.5% Nonidet P-40; 0.5 mM
EDTA; 2 mM PMSF; 1 ml/ml Protease Inhibitor Cocktail VI; 1
PBS). Samples were spun at 14,000 rpm for 10 minutes and the
supernatant retained for activity analysis. The TrxR activity was
measured in 0.5 M potassium phosphate, 200 mM EDTA, 20 mM
NADPH, with 125 mM DTNB. TNB production was measured by
following the increase in absorbance at 412 nm for 10 minutes.
The DC protein assay kit (BioRad, NSW, Australia) was used to
determine the concentration of proteins extracted from cells ac-
cording to manufacturer's instructions. Units of TrxR activity
(mmoles TNB produced/min) were calculated using an extinction
coefﬁcient of 13.6103 M1 for TNB at 412 nm. The speciﬁc ac-
tivity of thioredoxin reductase was determined using the following
equation: Speciﬁc activity (U/mg)¼U/total protein.
2.8. Monolayer scratch assays
This method was adapted from a previously described protocol
[43]. Before seeding out the cells, a scalpel was used to etch hor-
izontal and vertical lines, resulting in a cross at the center of each
well, on the underside of a 24-well plate. These lines were used as
reference points. Cells were seeded out and incubated at 37 °C
until they were 85-90% conﬂuent. The cells were then scratched
using a P1000 pipette tip to create a scratch passing through the
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and replaced with 10 mM thymidine containing media to act as an
anti-proliferative agent. Photos were taken of the scratches, in-
cluding the reference points, at 0, 24, and 48 h to monitor closure
of the scratch. At the start of each experiment, the distance mi-
grated by cells for each scratch-closure was designated as 0. The
distance migrated was calculated for 24 and 48 h based on the
reduction of the scratch width with respect to the 0 hour time
point. When recombinant Trx1 or the 1SS redox inactive mutated
form of human Trx1 was added to migration assays the samples
were ﬁrst reduced with DTT such that the wells contained a ﬁnal
concentration of 0.626 μM DTT. When applicable, the appropriate
concentration of auranoﬁn was added along with thymidine-
containing media.
2.9. ROS assays
Cells (1.5106) were grown in 6-well plates, after which 5 μM
H2DCF-DA (2′,7′–dichlorodihydroﬂuorescein diacetate) (Molecular
Probes, Vic, Australia) was added to the cells and incubated for
30 mins at 37°C. Cells were then lysed in 200 mL of ice-cold NP-40
lysis buffer (150 mM NaCl; 50 mM Tris-Cl, pH 8; 0.5% Nonidet
P-40; 0.5 mM EDTA; 2 mM PMSF; 1 ml/ml Protease Inhibitor
Cocktail VI; 1 PBS). The ﬂuorescence was measured using
495 nm excitation and 515 nm emission wavelengths with a
495 nm cut-off on the SpectraMax M3 plate reader (Molecular
Devices). The relative ﬂuorescence units (RFUs) were calculated
per mg of the total cellular protein (quantiﬁed using the DC pro-
tein assay kit from BioRad according to manufacturer’s instruc-
tions). Cells were also treated with the appropriate auranoﬁn
concentration for 24 h prior to incubation with H2DCF-DA.
2.10. Clonogenic assays
Cells (2106) were grown in 25 cm2 ﬂasks and treated with
appropriate concentrations of auranoﬁn for 24 hours. Cells were
then harvested and 1000 cells were seeded into 35 mm petri
dishes. Cells were then allowed to form colonies for 5 days at the
end of which, cells were washed with 1 PBS and ﬁxed with ice-
cold methanol. Crystal violet solution (0.5% (w/v) crystal violet and
25% (v/v) methanol) was then used to stain the colonies. The co-
lonies were washed with mqH2O three times and then counted.
2.11. Statistical analysis
Experimental data were analyzed by using the software GraphPad
Prism 6 (GraphPad Software, CA, USA). Values are presented as
mean7SEM. Statistical signiﬁcance was determined by the statistical
tests speciﬁed in the. po0.05 was considered signiﬁcant.3. Results
3.1. Over-expression of the Trx system in breast cancer patients
We ﬁrst investigated the expression of the Trx system in pa-
tient breast cancer samples. Using RNAseq data obtained from The
Cancer Genome Atlas (TCGA) portal we found that the expression
of both Trx1 and TrxR1 are statistically signiﬁcantly increased in
breast cancer patient cells compared with paired normal breast
tissue from the same patients (Fig. 1).
3.2. Thioredoxin in breast cancer cell invasion
Using an in vitro cell culture system we investigated the role
that Trx1 may play in cancer cell invasion. Stable transfectantswere made of MDA-MB-231 breast cancer cells using constructs
that over-expressed wild type Trx1, a mutated form of Trx1 with
both active site cysteines converted to serines (Trx-1SS), an anti-
sense Trx1 mRNA (Trx-as) and the vector (pcDNA3.1) as a control.
At least 4 clones for each transfection were selected and tested to
ensure they were expressing the correct construct. Transfectants
over-expressing wild type Trx1 showed a signiﬁcant increase in
invasion compared to the control clones, while transfectants ex-
pressing either the redox inactive form of Trx1 (Trx-1SS) or the
antisense form of Trx1 (Trx-as) showed a statistically signiﬁcant
decrease in invasion compared to control cells (Fig. 2). These re-
sults conﬁrm the role of Trx1 in the invasion of breast cancer cells
[28]. There was no signiﬁcant difference between clones trans-
fected with the antisense Trx1 construct or the redox inactive Trx-
1SS construct, suggesting each strategy was effective at disrupting
Trx1 function.
3.3. Exogenous Trx1 and breast cancer cell invasion
Since Trx1 is secreted from cancer cells [19,30,31,44], we also
assessed if addition of Trx1 into the extracellular environment had
an effect on the invasion of MDA-MB-231 cells. Addition of either
reduced or non-reduced Trx1 to the bottom well of the Boyden
chamber was shown to increase cell invasion of MDA-MB-231 cells
in a bell-shaped dose response (Fig. 3), similar to that observed in
studies showing Trx1 is chemotactic for neutrophils, monocytes
and T-cells [45]. The bell-shaped curve is characteristic of the re-
sponse exhibited by other chemokines [45]. There was no statis-
tical difference on cell invasion when comparing the addition of
reduced or non-reduced Trx1 at the same concentration.
3.4. Targeting the redox site of extracellular Trx1
Two speciﬁc anti-human Trx1 monoclonal antibodies were
used to determine if the redox function of Trx1 is required to
stimulate cell invasion. The monoclonal antibody 2B1 speciﬁcally
recognizes Trx1, but does not neutralize the active site, while the
antibody 9G9, binds to the active site region and inhibits the redox
activity of Trx1 [32]. These antibodies were added to either the
bottom or top well of the chamber and the invasion of the MDA-
MB-231 cells was assessed. The addition of the 2B1 monoclonal
antibody to either the top or bottom well did not result in any
statistically signiﬁcant change in cell invasion compared to cells
with no added antibody (Fig. 4). In contrast, the addition of the
9G9 monoclonal antibody to either the top or bottom well sig-
niﬁcantly decreased the level of invasion. These results indicate
that the redox activity of Trx1 is important for its role in invasion.
3.5. Effect of thioredoxin on migration
We also investigated the effect of Trx1 on cancer cell migration
through the use of in vitro monolayer scratch assays [43]. Stable
transfectants of the MDA-MB-231 cell line over-expressing either
wild type Trx1 or the 1SS redox inactive mutated form of Trx1
were used in these experiments. The wild type and 1SS constructs,
as used previously, were cloned into a GFP-expressing vector
(pIRES-EGFP) so that ﬂuorescence could be monitored to conﬁrm
ongoing expression from the construct. Stable transfectants of the
MDA-MB-231 cells were made using the pIRES-EGFP, pGFP-Trx
and pGFP-1SS constructs. At least 3 clones for each plasmid were
selected and tested to ensure they contained the correct construct.
In addition ROS levels were also determined in the 3 groups of
stable transfected cell lines to further characterize the intracellular
redox state of the cells. Cells expressing the 1SS construct had
signiﬁcantly higher ROS levels than the cells expressing either wild
type Trx1 or the empty vector (Fig. 5A).
Fig. 1. Expression of Trx1 and TrxR1 in patient breast cancer samples. The normalized gene expression levels (transcripts per million (TPM)) encoding Trx1 and TrxR1 were
analyzed according to the RNASeqV2 protocol using data obtained from the TCGA portal. Analysis was restricted to patients with matched tumor and normal samples
(n¼114). Both Trx1 and TrxR1 expression was shown to be statistically signiﬁcantly different in tumor samples compared to normal tissue, using a two-sample paired t test,
*po0.001, **po0.0001.
Fig. 2. Invasion of MDA-MB-231 transfectants in the Boyden chamber invasion
assay. DCC – Clones transfected with pcDNA3.1 vector only; DSC – Sense Trx1
clones; DAS – Antisense Trx1 clones; D1S – 1SS redox inactive Trx1 clones (n¼3).
Results from three independent experiments performed in triplicate are presented
as mean7SEM. A one-way ANOVA followed by Tukey's post test was employed
and a signiﬁcant difference in invasion values compared to the control cells is in-
dicated by *po0.05.
Fig. 3. Effect of exogenously added recombinant human Trx1 on MDA-MB-231 cell
invasion. Trx1 concentration is as indicated. SFM is serum free media (negative
control) and FBS (fetal bovine serum) in the bottom well was used as a positive
control. Results from three independent experiments performed in triplicate are
presented as mean7SEM. A two-way ANOVA followed by Tukey’s post test was
employed and a signiﬁcant difference in invasion values compared to the FBS
treated control cells and to other concentrations of Trx1 is indicated by *po0.05.
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assays. The representative images of the scratches monitored over
a period of 48 h are shown in Fig. 5B. As shown in Fig. 5B and C,
Trx1 over-expression (pGFP-Trx) did not cause any increase in the
migration of cells as compared to the control cells transfected with
the vector only (pIRES-EGFP). However, the cells over-expressing
the 1SS redox inactive form of Trx1 (pGFP-1SS) migrated slower
than the vector-only controls, with a signiﬁcant difference at the
48 hour time point when analyzed by a repeated measures two-
way ANOVA.3.6. Effect of extracellular Trx1 on migration
The effect of extracellular Trx1 on the migration of MDA-MB-231
breast cancer cells was tested. Wild type recombinant human Trx1
and the 1SS redox inactive mutated form of human Trx1 were reduced
with DTT and then incubated with MDA-MB-231 cells during mono-
layer scratch assays. Untreated cells were used as the control. At both
the 24 h and 48 h time points Trx1 exhibited a signiﬁcant effect on cell
migration compared to both the control cells and to the 1SS treated
Fig. 4. Effect of adding anti-Trx1 human monoclonal antibodies on the invasion of
MDA-MB-231 cells. Antibodies were added to either the top or bottom well of the
Boyden chamber. Results are from three independent experiments performed in
triplicate presented as mean7SEM. The invasion value is the cells/ﬁeld in the test
assay less the cells/ﬁeld in the negative control. A one-way ANOVA followed by
Tukey's post test was employed and a signiﬁcant difference in invasion values
compared to the control cells (Nil antibody added) is indicated by *po0.05.
Fig. 6. Differential effect of wild-type Trx1 and the 1SS redox inactive Trx1 form on
MDA-MB-231 breast cancer cell migration. Two different concentrations of wild-
type Trx1 or the 1SS redox inactive Trx1 form were used to treat MDA-MB-231
cells. Untreated cells were used as the control. Scratch closure was expressed as the
percentage scratch closure calculated at the 24 or 48 h time points using 0 hour
measurements as 0%. A two-way ANOVA employing Tukey's post test showed a
signiﬁcant difference between untreated cells and both the 0.313 μg/mL and
0.626 μg/mL Trx1 treated cells at 24 and 48 h incubation time, *po0.05. There was
also a difference between the Trx1 and 1SS redox inactive Trx1 treated cells at 24
and 48 h incubation time, Δpo0.05. Trx: Wild-type Trx1, 1SS: 1SS redox inactive
Trx1 form. Results are presented as mean7SEM from three independent experi-
ments conducted in quadruplicate.
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difference in migration. Other controls were also conducted, using DTT
at the same concentration as used to reduce Trx1, and recombinant
Trx1 that had been boiled, to ensure no other non-protein factors in
the sample were stimulating the migration. No change in cell migra-
tion was observed in either case (data not shown).Fig. 5. Effect of Trx1 on the migration of MDA-MB-231 cells. (A) ROS levels in stable transfected MDA-MB-231 cells analyzed using H2DCF-DA and represented as a fold
change over pIRES-EGFP transfected cells. A one-way ANOVA followed by Sidak’s post test was employed and showed that cells over-expressing the 1SS redox inactive Trx1
protein exhibited signiﬁcantly higher levels of ROS compared to the control cells, *po0.05. Results are presented as mean7SEM of three independent experiments
performed in triplicate. (B) Representative images of the transfected cells used in the monolayer scratch assays over a period of 48 h. The images were taken at 4 using a
Tucsen TCA 3MP camera and the scale bar is 50 mm. (C) Migration of stable transfected cells in response to over-expression of wild-type Trx1 and the 1SS redox inactive Trx1
protein. A repeated-measures two-way ANOVA followed by Sidak’s post test was employed and showed a statistical difference at 48 hour time point between 1SS over-
expressing cells and control cells, *po0.0001. Results are presented as mean7SEM of at least three independent experiments performed in quadruplicate.
Fig. 7. Effect of auranoﬁn induced inhibition of the TrxR system. (A) Proliferation of MDA-MB-231 cells in response to auranoﬁn treatment. The IC50 for auranoﬁn-induced
inhibition of MDA-MB-231 cell proliferation was determined to be 5.1 mM. At least three independent experiments were performed in triplicate. (B) TrxR1 speciﬁc activity in
MDA-MB-231 cells upon auranoﬁn treatment. Auranoﬁn signiﬁcantly inhibited the TrxR1 activity at 0.31 mM and higher concentrations, *po0.0001. A one-way ANOVA
followed by Sidak's post test was employed and results are presented as mean7SEM of at least three independent experiments performed in triplicate. (C) ROS levels in
auranoﬁn treated MDA-MB-231 cells analyzed using H2DCF-DA. A one-way ANOVA followed by Sidak’s post test was employed. Cells treated with 2 mM auranoﬁn had
signiﬁcantly higher levels of ROS compared to the control cells, *po0.05. (D) Migration of MDA-MB-231 cells in response to auranoﬁn treatment. Cells treated with 2mM
auranoﬁn showed a signiﬁcant decrease in the distance migrated as compared to the control cells, at both 24 and 48 h time points, *po0.0001. Data was analyzed using a
repeated measures two-way ANOVA followed by Sidak’s post test and results are presented as mean7SEM of three independent experiments.
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cell migration
Since Trx1 had been implicated in cancer cell migration we
used auranoﬁn, a potent anti-cancer drug, as a tool to inhibit the
Trx1 system. Auranoﬁn is a gold-based drug that irreversibly in-
hibits the activity of TrxR, resulting in a shift in the cellular redox
balance towards a less reduced state [46]. We ﬁrst assessed the
effect of a range of auranoﬁn concentrations on MDA-MB-231 cell
proliferation (Fig. 7A) and on TrxR activity (Fig. 7B). The IC50 for
cell proliferation was determined to be 5.1 mM and for TrxR activity
was 0.31 mM. For subsequent experiments we used two different
concentrations of auranoﬁn (0.31 mM and 2 mM), at which the TrxR
activity was inhibited without an effect on cell proliferation. An
increase in ROS levels was observed for auranoﬁn treated cells
compared to the untreated controls with a statistically signiﬁcant
difference observed when 2 mM auranoﬁn was used (Fig. 7C).
Next we examined the effect of auranoﬁn on the migration of
MDA-MB-231 cells using monolayer scratch assays. As shown in
Fig. 7D, at the higher concentration of 2 mM, auranoﬁn signiﬁcantly
inhibited the migration of the cells at both 24 and 48 h time points
compared to the untreated controls when analyzed by a repeated
measures two-way ANOVA. However, the lower concentration of
0.31 mM auranoﬁn did not affect cell migration.3.8. Auranoﬁn and clonogenic capacity of MDA-MB-231 cells
We also examined the effect of auranoﬁn treatment on the
clonogenic activity of MDA-MB-231 cells. Cells were treated with
0.31 mM and 2 mM auranoﬁn for 24 h and then seeded out for
colony formation over a period of 5 days. The representative
images are shown in Fig. 8A. As compared to the untreated cells,
no difference was observed in the number of colonies obtained
with cells treated with 0.31 mM auranoﬁn. However, treatment
with 2 mM auranoﬁn signiﬁcantly lowered the clonogenic capacity
of MDA-MB-231 cells with around 30% survival (Fig. 8B and C).
3.9. Thioredoxin system in the survival of breast cancer patients
We used a meta-analytical approach to investigate the evi-
dence linking the prognostic markers (Trx1 and TrxR1) with sur-
vival of breast cancer patients. We analyzed 25 independent co-
horts (the TCGA cohort and 24 microarray cohorts) containing a
total of 5910 patient samples. We prepared a forest plot (Fig. 9) to
identify any association between the Trx1 system and the overall
survival (OS) of patients, distant-metastasis free survival (DMFS)
and disease free survival (DFS) in each of these independent co-
horts. Overall survival refers to the time interval until breast
cancer associated death whereas disease free survival refers to
Fig. 8. Effect of auranoﬁn pre-treatment on the clonogenic capacity of MDA-MB-231 cells. (A) Representative images taken after 5 days of colony formation. (B) Number of
colonies obtained after 5 days. Cells that were pre-treated with 2 mM auranoﬁn had signiﬁcantly less number of colonies compared to the untreated cells, *po0.05. A one-
way ANOVA followed by Sidak's post test was employed and results are presented as mean7SEM of two independent experiments performed in duplicate. (C) Survival data
is presented as percentage of the untreated control cells.
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before any distant metastases are detected. In general, high levels
of Trx1 and TrxR1 are associated with poor outcomes. TrxR1 is
consistently associated with poor prognosis in all cohorts for OS
and DMFS, with the hazard ratio (HR)41 (Fig. 9). Trx1 is also
associated with poor patient outcomes in many of the cohorts.4. Discussion
Metastasis is the most life threatening aspect of breast cancer. It
is the process by which tumor cells detach from their primary
tissue, migrate and establish secondary tumors [47], which can be
far from the original tumor site and thus difﬁcult to detect. The
ﬁrst stage of metastasis is the detachment of cells from the pri-
mary tumor and attachment to the extracellular matrix (ECM),
which requires chemotactic migration of cancer cells [48,49].
Subsequently there is degradation of the ECM and entry of the
cells into the bloodstream [48]. The next step is the extravasation
of the cells from the circulation, degradation of the ECM of the
secondary tissue and establishment of a tumor colony with sub-
sequent proliferation [48,50]. In this paper we have shown that
the Trx1 system plays a role in cancer cell invasion, migration and
colony formation.
The Trx1 system is highly expressed in breast tumors [8,51] and
Trx1 has previously been suggested as a suitable serum marker
and diagnostic marker for breast cancer [35]. Our paper extends
these previous studies by using data obtained from a RNAseq
database to show that both Trx1 and TrxR1 are expressed at sta-
tistically signiﬁcant higher levels in breast tumor tissue compared
to the paired normal tissue from the same patient (Fig. 1). Bylimiting our analysis to the 114 patient samples that have paired
data, a stronger association can be made between the higher ex-
pression of both Trx1 and TrxR1 in tumor tissue compared to
normal tissue. This data suggests a role for the Trx1 system in
breast cancer carcinogenesis. Since high expression levels of Trx1
protein had been previously correlated with the most aggressive
and metastatic breast tumors [8] this current study was focused on
reﬁning the role of Trx1 in cancer cell invasion and migration.
Intracellular Trx1 had previously been shown to have a role in
breast cancer cell invasion using in vitro invasion assays [28]. Our
data conﬁrms the role of intracellular Trx1 in invasion since de-
creasing the levels of Trx1 in MDA-MB-231 breast cancer cells
using either an antisense approach or through expressing a redox
inactive Trx1 protein (1SS) resulted in decreased cell invasion. This
current study also extended previous results by showing that there
is a role for extracellular Trx1 in breast cancer cell invasion. Ad-
dition of wild type recombinant human Trx1 to the bottom well of
the invasion chamber resulted in increased cell invasion in a bell-
shaped dose response. This shows that Trx1 enhances the motility
of breast cancer cells.
Our results also suggest that the redox active site of Trx1 is
important for its extracellular role in cancer cell invasion. A spe-
ciﬁc monoclonal antibody (9G9) that binds to Trx1, and inhibits its
redox function, resulted in signiﬁcantly decreased cell invasion of
MDA-MB-231 cells. A speciﬁc monoclonal antibody (2B1) that
binds to Trx1, but does not interfere with its redox function did not
have any effect on cell invasion. The 9G9 antibody was able to
inhibit cell invasion when added to either the top or the bottom
well of the chamber, with no exogenous Trx1 added (Fig. 4). When
added to the bottom chamber it is likely that the antibody is in-
hibiting the action of secreted Trx1, thereby reducing breast cancer
Fig. 9. Breast cancer patient survival analysis. Survival analysis for Trx1 and TrxR1 using RNA sequencing data (TCGA cohort) as well as microarray data from 25 independent
cohorts, as indicated in the ﬁgure with associated number of patients. OS, overall survival; DMFS, distant metastasis-free survival; DFS, disease free survival. A forest plot
with the corresponding hazard ratios is shown on the right with the associated conﬁdence intervals indicated. Asterisks mark the results that are statistically signiﬁcant. A
hazard ratio (HR) 41 is indicative of a poor outcome.
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acting on either secreted Trx1 or on any cell surface bound Trx1.
Extracellular Trx1 has also been shown to destabilize the base-
ment membrane by reducing laminin and affecting its interaction
with galectin-3 in Matrigel based assays, thereby promoting en-
dothelial cell proliferation and spreading [52]. This effect was
found to be dependent on the Trx1 redox activity and was notobserved when the 1SS redox inactive Trx1 mutant was added
[52]. In the extracellular environment Trx1 was also shown to tip
the balance towards MMP function [29]. This suggests that ex-
tracellular Trx1 could be a therapeutic target to reduce the inva-
sion and therefore metastasis of breast cancer cells.
Cell migration is an important part of the metastatic process and
since Trx1 was shown to have a role in invasion, we therefore
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breast cancer cells. A low dose of a Trx1 inhibitor, PX-12, resulted in
decreased cell migration of colorectal cancer cells [53], raising the
possibility that Trx1 may have a role in regulating cancer cell mi-
gration. Whether this role involves either intracellular or extra-
cellular Trx1 in cancer cell migration was not established in the
previously published study [53]. However, PX-12 is not a suitable
drug for testing against MDA-MB-231 cells [54]. We therefore
modulated the levels of intracellular Trx1 through the transfection of
constructs that over-expressed wild type Trx1 and also the redox
inactive 1SS. Over-expression of intracellular Trx1 had no statistically
signiﬁcant effect on cell migration, but intracellular expression of 1SS
resulted in statistically signiﬁcantly decreased cell migration. It is
possible that the endogenous Trx1 levels were sufﬁcient to stimulate
the migration of cells and therefore the Trx1 protein over-expressed
from the transgene did not exhibit any additional effect on the cell
migration. This may be the reason why the distance migrated by
pGFP-Trx cells as well as the ROS levels in these cells were similar to
those observed for the pIRES-EGFP control cells. Furthermore, 1SS
over-expression may be blocking the endogenous Trx1 by acting as a
competitive inhibitor for TrxR1 in the intracellular environment.
Therefore, a decrease in cell migration was observed compared to
cells transfected with only the vector.
Extracellular Trx1 levels were modiﬁed by adding either re-
combinant human wild type Trx1 or 1SS. Addition of wild type
Trx1 enhanced migration while addition of the equivalent con-
centration of 1SS had no effect on migration of cells. This result
correlates with the chemotactic properties exhibited by Trx1, but
not by 1SS, towards monocytes and polymorphonuclear neu-
trophils [55]. Exogenously added 1SS has previously been shown
to be incapable of binding to the cell surface of adult T-cell leu-
kemia (ATL) cells, whereas wild type Trx1 was able to bind, sug-
gesting that a disulﬁde bond is involved in cell surface binding
[56]. Therefore, exogenously added 1SS may have failed to en-
hance cell migration because it lacks the ability to interact with
Trx1 cell surface targets. Overall these data suggest that the redox
site of Trx1 is required for both its intracellular and extracellular
functions with respect to cell migration.
Auranoﬁn is a gold-containing compound known to inhibit TrxR
activity [46] and has previously been shown to inhibit proliferation
of cancer cell lines, including the MDA-MB-231 cell line [57]. Cur-
rently auranoﬁn is being tested in phase I/II clinical trials for the
treatment of chronic lymphocytic leukemia, small lymphocytic leu-
kemia and prolymphocytic lymphoma [58]. Auranoﬁn was reported
to decrease VEGF mRNA levels of human umbilical vein endothelial
cells (HUVEC) and decreased endothelial cell migration in monolayer
scratch assays. In a separate study, auranoﬁn was shown to down-
regulate the VEGFR3-mediated migration of endothelial cells [59].
We therefore tested auranoﬁn on the migration of breast cancer cells.
Addition of auranoﬁn was shown to inhibit the migration of MDA-
MB-231 cells, compared to untreated cells, at the 2 μM concentra-
tion, at which TrxR activity was inhibited without an effect on cell
proliferation. This result suggests that inhibiting TrxR activity is a
possible therapeutic strategy for targeting the cell migration com-
ponent of the cancer metastatic process.
Clonogenic assays were also performed to assess if pre-treat-
ment with auranoﬁn has any effect on the ability of breast cancer
cells to form secondary colonies in a drug-free environment. Pre-
treatment with auranoﬁn resulted in an inhibition of colony for-
mation at the higher concentration (2 μM), which correlated with
the concentration of auranoﬁn that inhibited cell migration.
Therefore, auranoﬁn can target two components of the metastatic
pathway, cell migration and colonization.
We showed that high levels of Trx1 and TrxR1 expression are
correlated with poor patient outcomes in terms of survival and
metastases formation. A previous study showed that TrxR1 andthioredoxin interacting protein (TXNIP) are associated with prog-
nosis in breast cancer [60]. High levels of TrxR1 were associated
with worse metastasis free survival, disease free survival and
overall survival. In contrast high levels of TXNIP were associated
with better metastasis-free survival [60]. Our results were based
on the analysis of data from a much larger sample size comprising
25 independent cohorts containing a total of 5910 patient samples,
including 1071 RNA seq samples from the TCGA database. We
found similar results to the previous study in that high levels of
TrxR1 are associated with a poor patient prognosis. TrxR1 is
strongly associated with poor outcomes in terms of overall survi-
val, disease free survival and distant metastasis free survival in all
of the independent cohorts. We also assessed the link between Trx
and breast cancer prognosis. Our results support the previous
smaller study in showing that Trx was associated with worse
metastasis free survival [60], although not all independent cohorts
were statistically signiﬁcant in our study. In addition to the me-
tastasis free survival reported in the previous study, we also as-
sessed disease free survival and overall survival, with high levels of
Trx again associated with a poor prognosis. However statistical
signiﬁcance associating Trx 1 with a poor prognosis was obtained
for a lower number of cohorts than that observed for TrxR1, in-
dicating that TrxR1 may be a better prognostic indicator.
The association of high levels of Trx1 and TrxR1 expression
with both survival and formation of distant metastases correlates
with its roles in in vitro cancer cell invasion and migration as
shown in this current study. Therefore, targeting the function of
TrxR by drugs such as auranoﬁn, or using other Trx system in-
hibitors, in combination with other therapeutic agents may offer
an opportunity to reduce metastases and enhance survival for
breast cancer patients.Acknowledgments
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